Where Tech Meets Bio | BiopharmaTrend | Substack

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent

Jul 2 • Andrii Buvailo, PhD

My Seven Health Tech Observations From HLTH Europe 2026 Event

AI is moving from writing clinical notes to checking them. "Human-in-the-loop" is becoming a product, not a footnote. Nearly everyone is racing to own…

Jun 26 • Andrii Buvailo, PhD

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain).

Jun 1 • Andrii Buvailo, PhD

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

May 21 • Andrii Buvailo, PhD and Roman Kasianov

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune…

Apr 16 • Louise von Stechow and BiopharmaTrend

Most Popular

Cancer as a Data Problem: What AI Is Doing in Oncology

Feb 27 • BiopharmaTrend

Five Genomics Watchpoints for 2026

Feb 20 • BiopharmaTrend

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Jan 15 • BiopharmaTrend

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Mar 7 • BiopharmaTrend

Join 11k+ biotech industry professionals tracking strategy signals in the 'techbio' space

Sponsored Features

On Predicting Probability of Technical and Regulatory Success With AI

Insights from The American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Nov 7, 2024 • BiopharmaTrend

Using AI to Predict the Probability of Success in Drug Development

ALSO: Patented AI Platform Identifies Promising Early-Stage Biopharma Assets and Companies

Jun 13, 2024

Building Data Infrastructure for Biology

ALSO: Featuring Omics Solution Providers Market Map, from Multiomics to Spatial Biology

May 23, 2024

49:15

Enabling Precision Medicine with AI

A Deep Dive with Lantern Pharma's CEO, Panna Sharma

Mar 7, 2024 • Andrii Buvailo, PhD

Deep Dives

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent

Jul 2 • Andrii Buvailo, PhD

My Seven Health Tech Observations From HLTH Europe 2026 Event

AI is moving from writing clinical notes to checking them. "Human-in-the-loop" is becoming a product, not a footnote. Nearly everyone is racing to own…

Jun 26 • Andrii Buvailo, PhD

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain).

Jun 1 • Andrii Buvailo, PhD

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

May 21 • Andrii Buvailo, PhD and Roman Kasianov

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune…

Apr 16 • Louise von Stechow and BiopharmaTrend

Recommendations

Forever.AI: AI, Robotics, Quantum, Longevity, Cryonics & BCI

Alex Zhavoronkov, PhD

Molecules & Empires

Andrii Buvailo, PhD

Special Competitive Studies Project

SCSP

The Connected Ideas Project

Alexander Titus

Recent posts

Weekly Tech+Bio #81: AI Agents at the Cancer Conference

AI-pharma deals track toward a 12x increase in five years, Life Biosciences takes cell reprogramming to Phase 1, and Jeito closes Europe's largest…

Apr 14 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

Weekly Tech+Bio #80: Organoids on Artemis II

Anthropic's $400M AI biotech acqui-hire, CRO stocks reprice, new EMA draft, and pharma's spring acquisition spree

Apr 6 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

Everyone is Launching AI Agents. What's Being Deployed?

A check-in on biopharma's agentic AI buildout

Apr 4 • Roman Kasianov and Andrii Buvailo, PhD

Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg

Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science

Mar 30 • Roman Kasianov and Andrii Buvailo, PhD

The latest from

Andrii Buvailo, PhD

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

Roman Kasianov

Is “Rescuing Failed Drugs with AI” a Category Now?

BiopharmaTrend

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts